ORTX — Orchard Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $378.06m
- $278.24m
- $22.66m
Annual cashflow statement for Orchard Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -230 | -163 | -152 | -145 | -151 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 95.2 | 13.3 | 29.6 | 33.1 | 39 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 36.5 | -17.7 | -3.63 | -17.1 | 36.2 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -97.5 | -166 | -126 | -125 | -76 |
| Capital Expenditures | -4.03 | -4.37 | -2.67 | -2.35 | -6.51 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -305 | 160 | -29.8 | 97.1 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -4.03 | -309 | 157 | -32.2 | 90.6 |
| Financing Cash Flow Items | — | -0.605 | — | -6.75 | -0.119 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 355 | 157 | 3.94 | 158 | -0.693 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 250 | -316 | 36.1 | 0.777 | 12.5 |